158 related articles for article (PubMed ID: 10561184)
21. Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome.
Lokhorst HM; Schattenberg A; Cornelissen JJ; van Oers MH; Fibbe W; Russell I; Donk NW; Verdonck LF
J Clin Oncol; 2000 Aug; 18(16):3031-7. PubMed ID: 10944138
[TBL] [Abstract][Full Text] [Related]
22. Partial T cell-depleted allogeneic stem cell transplantation following reduced-intensity conditioning creates a platform for immunotherapy with donor lymphocyte infusion and recipient dendritic cell vaccination in multiple myeloma.
Levenga H; Schaap N; Maas F; Esendam B; Fredrix H; Greupink-Draaisma A; de Witte T; Dolstra H; Raymakers R
Biol Blood Marrow Transplant; 2010 Mar; 16(3):320-32. PubMed ID: 19835972
[TBL] [Abstract][Full Text] [Related]
23. Prospective trial of high-dose chemotherapy followed by infusions of peripheral blood stem cells and dose-escalated donor lymphocytes for relapsed leukemia after allogeneic stem cell transplantation.
Takami A; Okumura H; Yamazaki H; Kami M; Kim SW; Asakura H; Endo T; Nishio M; Minauchi K; Kumano K; Sugimori N; Mori S; Takemoto Y; Shimadoi S; Ozaki J; Takaue Y; Nakao S
Int J Hematol; 2005 Dec; 82(5):449-55. PubMed ID: 16533751
[TBL] [Abstract][Full Text] [Related]
24. Donor Lymphocyte Infusions Used to Treat Mixed-Chimeric and High-Risk Patient Populations in the Relapsed and Nonrelapsed Settings after Allogeneic Transplantation for Hematologic Malignancies Are Associated with High Five-Year Survival if Persistent Full Donor Chimerism Is Obtained or Maintained.
Caldemeyer LE; Akard LP; Edwards JR; Tandra A; Wagenknecht DR; Dugan MJ
Biol Blood Marrow Transplant; 2017 Nov; 23(11):1989-1997. PubMed ID: 28712934
[TBL] [Abstract][Full Text] [Related]
25. Pilot study of prophylactic ex vivo costimulated donor leukocyte infusion after reduced-intensity conditioned allogeneic stem cell transplantation.
Kumar AJ; Hexner EO; Frey NV; Luger SM; Loren AW; Reshef R; Boyer J; Smith J; Stadtmauer EA; Levine BL; June CH; Porter DL; Goldstein SC
Biol Blood Marrow Transplant; 2013 Jul; 19(7):1094-101. PubMed ID: 23635453
[TBL] [Abstract][Full Text] [Related]
26. Allogeneic hematopoietic stem cell transplantation in ovarian carcinoma: results of five patients.
Bay JO; Fleury J; Choufi B; Tournilhac O; Vincent C; Bailly C; Dauplat J; Viens P; Faucher C; Blaise D
Bone Marrow Transplant; 2002 Jul; 30(2):95-102. PubMed ID: 12132048
[TBL] [Abstract][Full Text] [Related]
27. Reduced intensity conditioning: enhanced graft-versus-tumor effect following dose-reduced conditioning and allogeneic transplantation for refractory lymphoid malignancies after high-dose therapy.
Mohty M; Fegueux N; Exbrayat C; Lu ZY; Legouffe E; Quittet P; Lopez-Martinez E; Latry P; Avinens O; Hertog C; Klein B; Eliaou JF; Rossi JF
Bone Marrow Transplant; 2001 Aug; 28(4):335-9. PubMed ID: 11571504
[TBL] [Abstract][Full Text] [Related]
28. Lymphohematopoietic graft-vs.-host reactions can be induced without graft-vs.-host disease in murine mixed chimeras established with a cyclophosphamide-based nonmyeloablative conditioning regimen.
Pelot MR; Pearson DA; Swenson K; Zhao G; Sachs J; Yang YG; Sykes M
Biol Blood Marrow Transplant; 1999; 5(3):133-43. PubMed ID: 10392959
[TBL] [Abstract][Full Text] [Related]
29. Individually adjusted prophylactic donor lymphocyte infusions after CD34-selected allogeneic peripheral blood stem cell transplantation.
Ferrá C; Rodríguez-Luaces M; Gallardo D; Encuentra M; Martín-Henao GA; Peris J; Ancín I; Sarrá J; Berlanga JJ; García J; Grañena A
Bone Marrow Transplant; 2001 Nov; 28(10):963-8. PubMed ID: 11753552
[TBL] [Abstract][Full Text] [Related]
30. Chimerism-based pre-emptive immunotherapy with fast withdrawal of immunosuppression and donor lymphocyte infusions after allogeneic stem cell transplantation for pediatric hematologic malignancies.
Horn B; Petrovic A; Wahlstrom J; Dvorak CC; Kong D; Hwang J; Expose-Spencer J; Gates M; Cowan MJ
Biol Blood Marrow Transplant; 2015 Apr; 21(4):729-37. PubMed ID: 25644958
[TBL] [Abstract][Full Text] [Related]
31. Graft-versus-host disease after donor leukocyte infusions: presentation and management.
Frey NV; Porter DL
Best Pract Res Clin Haematol; 2008 Jun; 21(2):205-22. PubMed ID: 18503987
[TBL] [Abstract][Full Text] [Related]
32. High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphoma.
Bloor AJ; Thomson K; Chowdhry N; Verfuerth S; Ings SJ; Chakraverty R; Linch DC; Goldstone AH; Peggs KS; Mackinnon S
Biol Blood Marrow Transplant; 2008 Jan; 14(1):50-8. PubMed ID: 18158961
[TBL] [Abstract][Full Text] [Related]
33. Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed hematologic malignancy following autologous stem cell transplantation.
Dey BR; McAfee S; Sackstein R; Colby C; Saidman S; Weymouth D; Poliquin C; Vanderklish J; Sachs DH; Sykes M; Spitzer TR
Biol Blood Marrow Transplant; 2001; 7(11):604-12. PubMed ID: 11760148
[TBL] [Abstract][Full Text] [Related]
34. Cytokine expression in tumors treated with donor lymphocyte infusions after allogeneic hematopoietic stem cell transplantation.
Conrad R; Remberger M; Cederlund K; Barkholt L
Immunotherapy; 2011 Mar; 3(3):443-51. PubMed ID: 21395385
[TBL] [Abstract][Full Text] [Related]
35. Graft-versus-leukemia effects from donor lymphocyte infusion after nonmyeloablative allogeneic bone marrow transplantation in mice.
Du B; Li DP; Xu KL; Pan XY
Chin Med J (Engl); 2005 Mar; 118(6):474-9. PubMed ID: 15788128
[TBL] [Abstract][Full Text] [Related]
36. Allogeneic peripheral blood progenitor cells for treatment of relapse after bone marrow transplantation.
Glass B; Majolino I; Dreger P; Scimè R; Santoro A; Vasta S; Suttorp M; Haferlach T; Schmitz N
Bone Marrow Transplant; 1997 Oct; 20(7):533-41. PubMed ID: 9337054
[TBL] [Abstract][Full Text] [Related]
37. Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning.
Bethge WA; Hegenbart U; Stuart MJ; Storer BE; Maris MB; Flowers ME; Maloney DG; Chauncey T; Bruno B; Agura E; Forman SJ; Blume KG; Niederwieser D; Storb R; Sandmaier BM
Blood; 2004 Feb; 103(3):790-5. PubMed ID: 14525766
[TBL] [Abstract][Full Text] [Related]
38. Graft-versus-host reactions and the effectiveness of donor lymphocyte infusions.
Huff CA; Fuchs EJ; Smith BD; Blackford A; Garrett-Mayer E; Brodsky RA; Flinn IW; Ambinder RF; Borrello IM; Matsui WH; Vogelsang GB; Griffin CA; Luznik L; Jones RJ
Biol Blood Marrow Transplant; 2006 Apr; 12(4):414-21. PubMed ID: 16545725
[TBL] [Abstract][Full Text] [Related]
39. Donor CD3(+) lymphocyte infusion after reduced intensity conditioning allogeneic stem cell transplantation: single-center experience.
El-Cheikh J; Crocchiolo R; Furst S; Ladaique P; Castagna L; Faucher C; Calmels B; Oudin C; Lemarie C; Granata A; Devillier R; Vey N; Bouabdallah R; Chabannon C; Blaise D
Exp Hematol; 2013 Jan; 41(1):17-27. PubMed ID: 23022128
[TBL] [Abstract][Full Text] [Related]
40. Allogeneic hematopoietic cell transplantation for metastatic renal cell carcinoma after nonmyeloablative conditioning: toxicity, clinical response, and immunological response to minor histocompatibility antigens.
Tykodi SS; Warren EH; Thompson JA; Riddell SR; Childs RW; Otterud BE; Leppert MF; Storb R; Sandmaier BM
Clin Cancer Res; 2004 Dec; 10(23):7799-811. PubMed ID: 15585611
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]